Please login to the form below

Not currently logged in
Email:
Password:

Neurimmune

This page shows the latest Neurimmune news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

There is still plenty of clinical trial activity on the go in the amyloid area, however, with late-stage studies ongoing for candidates including Biogen/Neurimmune’s aducanumab, Roche/AC

Latest news

  • Biogen Idec claims first with Alzheimer's candidate Biogen Idec claims first with Alzheimer's candidate

    Biogen Idec licensed aducanumab from Swiss company Neurimmune in 2007. It was derived from antibodies taken from donors who were cognitively normal despite advanced age, on the hypothesis that these donors'

  • Biogen Idec plans phase III Alzheimer's trial before year-end Biogen Idec plans phase III Alzheimer's trial before year-end

    BIIB037 - also known as aducanumab and originally developed by Swiss biotech Neurimmune - is an antibody targeting beta amyloid protein, which builds up in the brain in Alzheimer's patients and is

  • Eisai and Biogen partner on Alzheimer’s Eisai and Biogen partner on Alzheimer’s

    Biogen Idec's CEO George Scangos said the deal fitted into Biogen Idec's current activities in Alzheimer's, which includes a 2010 deal with Neurimmune to use immunotherapies to treat

  • Survival strategy

    Phase Ib. 512. SmartCells/Merck. Glucose responsive insulin formulation. Preclinical. 500. Neurimmune/Biogen.

  • Biogen targets neurodegenerative diseases

    Biogen Idec is to acquire a subsidiary of Neurimmune, including the worldwide rights to three pre-clinical immunotherapy programmes. ... Neurimmune continues to impress us with its ability to translate scientific insights into innovative antibodies for

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Neurimmune appoints chief business officer Neurimmune appoints chief business officer

    Prior to joining Neurimmune, Buller served as director new ventures at Johnson &Johnson Innovation, as well as director of business development of Covagen. ... Roger Nitsch, president and CEO of Neurimmune, said: “We are pleased that Dr Buller joins

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics